Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis

G. Ristori, M. G. Buzzi, U. Sabatini, E. Giugni, S. Bastianello, F. Viselli, C. Buttinelli, S. Ruggieri, C. Colonnese, C. Pozzilli, M. Salvetti

Research output: Contribution to journalArticlepeer-review


We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.

Original languageEnglish
Pages (from-to)1588-1589
Number of pages2
Issue number7
Publication statusPublished - Oct 22 1999


  • Bacille Calmette-Guerin
  • MS
  • Therapy
  • Vaccine

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Use of Bacille Calmette-Guerin (BCG) in multiple sclerosis'. Together they form a unique fingerprint.

Cite this